Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 3: 618 - 626

DOI: https://doi.org/10.19852/j.cnki.jtcm.20230404.002

Reviews

Farnesoid X receptor regulators from natural products and their biological function

  • Wan PENG ,
  • Hengfan NI ,
  • Dale GUO ,
  • Yun DENG ,
  • Manyun DAI
Expand
  • 1 Institute of Rare Diseases, West China Hospital, Sichuan University, Chengdu 610065, China
    2 Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China
    3 School of Pharmacy, Chengdu University of Traditional Chinese Medicine, State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu 611137, China
    4 School of Medicine, Ningbo University, Ningbo 315000, China

Received date: 2022-11-18

  Accepted date: 2023-02-27

  Online published: 2023-04-04

Supported by

Study on Coptidis Rhizoma’s Therapeutic Mechanism of Diabetes Mellitus and Innovation of Relative Drug based on DNA Encoded Compound Library Technology(U19A2011);Discovery of Active Components Reshaping Tumor Immune Microenvironment Based on Feature Gene Expression Profile of Sichuan’s Characteristic Medicinal Materials(ZDZX2022002)

Fold

Abstract

Metabolic syndrome (MetS) has been a growing public health concern worldwide without specific medicine. Through summarizing the chemical structure type and effect mechanisms of natural products targeted on farnesoid X receptor (FXR), to provide the research basis for exploring the treatment of MetS. The following databases were searched for natural products which targeting FXR: PubMed, Embase, the Cochrane Library, Web of Science, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biomedical Literature Database. Totally 120 natural products were summarized, including terpenoids (51 compounds), steroidal saponins (27 compounds), phenylpropanolds (19 compounds), flavonoids (13 compounds), alkaloids (3 compounds) and others (7 compounds), most researches focus on terpenoids and part of synthetic FXR regulators were based on the structure of terpenoids. FXR regulators could improve cholestasis and liver injury, hyperlipidemia, diabetes and atherosclerosis. FXR is a potential target of treating MetS. Natural products are characteristics with unique novel structures and special biological activity, and they are important sources of bioactive precursor compounds and drug discovery. Exploring the effects and mechanism of natural products and its derivative on MetS by targeting FXR may be a new way to develop the new drugs of treating MetS.

Key words： farnesoid X receptor; metabolic syndrome; biological products; molecular docking simulation; biological activity

Cite this article

Wan PENG , Hengfan NI , Dale GUO , Yun DENG , Manyun DAI . Farnesoid X receptor regulators from natural products and their biological function[J]. Journal of Traditional Chinese Medicine, 2023 , 43(3) : 618 -626 . DOI: 10.19852/j.cnki.jtcm.20230404.002

References

[1] Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and international association for the study of obesity. Circulation 2009; 120: 1640-5.
[2] Cano-Ibá?ez N, Gea A, Martínez-González MA, et al. Dietary diversity and nutritional adequacy among an older Spanish population with metabolic syndrome in the PREDIMED-plus study: a cross-sectional analysis. Nutrients 2009; 11: 958.
[3] Garralda-Del-Villar M, Carlos-Chillerón S, Diaz-Gutierrez J, et al. Healthy lifestyle and incidence of metabolic syndrome in the SUN cohort. Nutrients 2018; 11: 65.
[4] Saklayen MG. The global epidemic of the metabolic syndrome. Current Hypertension Reports 2018; 20: 12.
[5] Julibert A, Bibiloni MDM, Mateos D, Angullo E, Tur JA. Dietary fat intake and metabolic syndrome in older adults. Nutrients 2019; 11: 1901.
[6] Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687-93.
[7] Wang H, He Q, Wang G, Xu X, Hao H. FXR modulators for enterohepatic and metabolic diseases. Expert Opin Ther Pat 2018; 28: 765-82.
[8] Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103: 3920-5.
[9] Wang H, Cao G, Wang G, Hao H. Regulation of mammalian UDP-glucuronosyltransferases. Curr Drug Metab 2018; 19: 490-501.
[10] Quigley EM. Primary biliary cirrhosis and the microbiome. Semin Liver Dis 2016; 36: 349-53.
[11] Wang L, Li J, Liu H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2013; 28 Suppl 1: 85-92.
[12] Duran-Sandoval D, Cariou B, Percevault F, et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005; 280: 29971-9.
[13] Shin D, Kongpakpaisarn K, Bohra C. Trends in the prevalence of metabolic syndrome and its components in the United States 2007-2014. Int J Cardiol 2018; 259: 216-9.
[14] Ekiert HM, Szopa A. Biological activities of natural products. Molecules 2020; 25: 5769.
[15] Ran D, Hong W, Yan W, Mengdie W. Properties and molecular mechanisms underlying geniposide-mediated therapeutic effects in chronic inflammatory diseases. J Ethnopharmacol 2021; 273: 113958.
[16] Chen H, Huang X, Min J, et al. Geniposidic acid protected against ANIT-induced hepatotoxity and acute intrahepatic cholestasis, due to Fxr-mediated regulation of Bsep and Mrp2. J Ethnopharmacol 2016; 179: 197-207.
[17] Liu J, Li Y, Sun C, et al. Geniposide reduces cholesterol accumulation and increases its excretion by regulating the FXR-mediated liver-gut crosstalk of bile acids. Pharmacol Res 2020; 152: 104631.
[18] Li T, Xu L, Zheng R, et al. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor. Phytomedicine 2020; 68: 153153.
[19] Li Y, Chen H, Ke Z, et al. Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice. Biochem Biophys Res Commun 2020; 521: 639-45.
[20] Gong J, Yang F, Yang Q, et al. Sweroside ameliorated carbon tetrachloride (CCl4)-induced liver fibrosis through FXR-miR-29a signaling pathway. J Nat Med 2020; 74: 17-25.
[21] Choi H, Hwang H, Chin J, et al. Tuberatolides, potent FXR antagonists from the Korean marine tunicate Botryllus tuberatus. J Nat Prod 2011; 74: 90-4.
[22] Lin HR. Lepidozenolide from the liverwort Lepidozia fauriana acts as a farnesoid X receptor agonist. J Asian Nat Prod Res 2015; 17: 149-58.
[23] Zheng W, Lu Y, Lin S, et al. A novel class of natural FXR modulators with a unique mode of selective co-regulator assembly. Chembiochem 2017; 18: 721-5.
[24] Tsai CJ, Liang JW, Lin HR. Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators. Bioorg Med Chem Lett 2012; 22: 2326-9.
[25] Ricketts ML, Boekschoten MV, Kreeft AJ, et al. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol Endocrinol 2007; 21: 1603-16.
[26] Epifano F, Genovese S, James Squires E, Gray MA. Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist. Bioorg Med Chem Lett 2012; 22: 3130-5.
[27] Han X, Cui ZY, Song J, et al. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. Chem Biol Interact 2019; 311: 108794.
[28] Suzuki T, Nishimaki-Mogami T, Kawai H, et al. Screening of novel nuclear receptor agonists by a convenient reporter gene assay system using green fluorescent protein derivatives. Phytomedicine 2006; 13: 401-11.
[29] Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296: 1703-6.
[30] Wu J, Xia CS, Meier J, Li SZ, Hu X, Lala DS. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 2002; 16: 1590-7.
[31] Cui J, Huang L, Zhao A, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003; 278: 10214-20.
[32] Diao Y, Jiang J, Zhang S, et al. Discovery of natural products as novel and potent FXR antagonists by virtual screening. Front Chem 2018; 6: 140.
[33] Xu X, Lul Y, Chen LL, Chen J, Luo XM, Shen X. Identification of 15d-PGJ(2) as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation. Steroids 2013; 78: 813-22.
[34] Song M, Yang Q, Zhang FL, et al. Hyodeoxycholic acid (HDCA) suppresses intestinal epithelial cell proliferation through FXR-PI3K/AKT pathway, accompanied by alteration of bile acids metabolism profiles induced by gut bacteria. FASEB J 2020; 34: 7103-17.
[35] Nam SJ, Ko H, Shin M, et al. Farnesoid X-activated receptor antagonists from a marine sponge spongia sp. Bioorg Med Chem Lett 2006; 16: 5398-402.
[36] Nam SJ, Ko H, Ju MK, et al. Scalarane sesterterpenes from a marine sponge of the genus spongia and their FXR antagonistic activity. J Nat Prod 2007; 70: 1691-5.
[37] Xiao Q, Zhang S, Ren H. et al. Ginsenoside Rg1 alleviates ANIT-induced intrahepatic cholestasis in rats via activating farnesoid X receptor and regulating transporters and metabolic enzymes. Chem Biol Interact 2020; 324: 109062.
[38] Meng Q, Chen XL, Wang CY, et al. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis. Toxicol Appl Pharmacol 2015; 283: 178-86.
[39] Lin HR. Triterpenes from alisma orientalis act as farnesoid X receptor agonists. Bioorg Med Chem Lett 2012; 22: 4787-92.
[40] Lu Y, Zheng W, Lin S, et al. Identification of an oleanane-type triterpene hedragonic acid as a novel farnesoid X receptor ligand with liver protective effects and anti-inflammatory activity. Mol Pharmacol 2018; 93: 63-72.
[41] Gu M, Zhang S, Zhao Y, et al. Cycloastragenol improves hepatic steatosis by activating farnesoid X receptor signalling. Pharmacol Res 2017; 121: 22-32.
[42] Wu SY, Cui SC, Wang L, et al. 18beta-glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway. Acta Pharmacol Sin 2018; 39: 1865-73.
[43] Zhao Q, Liu F, Cheng Y, et al. Celastrol protects from cholestatic liver injury though modulation of SIRT1-FXR signaling. Mol Cell Proteomics 2019: 520-33.
[44] Chen P, Li J, Fan X, et al. Oleanolic acid attenuates obstructive cholestasis in bile duct-ligated mice, possibly via activation of NRF2-MRPs and FXR antagonism. Eur J Pharmacol 2015; 765: 131-9.
[45] Kopustinskiene DM, Bernatoniene J. Antioxidant effects of schisandra chinensis fruits and their active constituents. Antioxidants (Basel) 2021; 10: 620.
[46] Zou J, Jiang J, Diao YY, et al. Cycloartane triterpenoids from the stems of schisandra glaucescens and their bioactivity. Fitoterapia 2012; 83: 926-31.
[47] Zou J, Yang LB, Jiang J, et al. Lanostane triterpenoids from the stems of schisandra glaucescens. Planta Med 2012; 78: 472-9.
[48] Gü?lü-Ustünda? O, Mazza G. Saponins: properties, applications and processing. Crit Rev Food Sci Nutr 2007; 47: 231-58.
[49] Grienke U, Mihaly-Bison J, Schuster D, et al. Pharmacophore-based discovery of FXR-agonists. part II: identification of bioactive triterpenes from ganoderma lucidum. Bioorg Med Chem 2011; 19: 6779-91.
[50] Zhang Y, Xu Y, Qi Y, et al. Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation. Toxicology 2017; 378: 53-64.
[51] Sepe V, Ummarino R, D'Auria MV, et al. Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge theonella swinhoei. J Med Chem 2012; 55: 84-93.
[52] Zou SL, Liu J, Lan Y, Cheng H, Gan XL. Effects of farnesoid X receptor ligand on the metabolism of bile acids in rats with estrogen-induced intrahepatic cholestasis of pregnancy. Zhong Hua Gan Zang Bing Za Zhi 2008; 16: 383-6.
[53] Li X, Niu C, Mao W, Guan H, He X, Li P. Effects of taurochenodeoxycholic acid on the expression amount of FXR related to fat metabolism in rat liver. Chin J Vet Sci 2018; 38: 1430.
[54] De Marino S, Ummarino R, D'Auria MV, et al. Theonellasterols and conicasterols from Theonella swinhoei. novel marine natural ligands for human nuclear receptors. J Med Chem 2011; 54: 3065-75.
[55] Carter BA, Taylor OA, Prendergast DR, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 2007; 62: 301-6.
[56] Li F, Jiang C, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013; 4: 2384.
[57] Shin K, Chin J, Hahn D, et al. Sterols from a soft coral, Dendronephthya gigantea as farnesoid X-activated receptor antagonists. Steroids 2012; 77: 355-9.
[58] Sepe V, Bifulco G, Renga B, D'Amore C, Fiorucci S, Zampella A. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. J Med Chem 2011; 54: 1314-20.
[59] Putra MY, Bavestrello G, Cerrano C, et al. Polyhydroxylated sterols from the indonesian soft coral sinularia sp. and their effect on farnesoid X-activated receptor. Steroids 2012; 77: 433-40.
[60] Renga B, Mencarelli A, D'Amore C, et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One 2012; 7: e30443.
[61] Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med 2018; 24: 1919-29.
[62] Jain PG, Surana SJ. Hypolipidemic activity of Prosopis cineraria L (Druce) fruit extract and molecular modeling study with farnesoid X receptor (FXR). Trop J Pharm Res 2015; 14: 1621-8.
[63] Yuan Y, Wu X, Hong Y, Zhang X, Wang Z, Yan H. Salidroside ameliorates liver metabonomics in relation to modified gut-liver FXR signaling in furan-induced mice. Food Chem Toxicol 2020; 140: 111311.
[64] Gao Z, Zhang J, Wei L, et al. The protective effects of imperatorin on acetaminophen overdose-induced acute liver injury. Oxid Med Cell Longev 2020; 2020: 8026838.
[65] He Y, Fan Q, Cai T, et al. Molecular mechanisms of the action of arctigenin in cancer. Biomed Pharmacother 2018; 108: 403-7.
[66] Chen X, Lu F, Luo G, Ren Y, Ma J, Zhang Y. Discovery of selective farnesoid X receptor agonists for the treatment of hyperlipidemia from traditional chinese medicine based on virtual screening and in vitro validation. J Biomol Struct Dyn 2019: 1-10.
[67] Suzuki T, Tamehiro N, Sato Y, et al. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J Pharmacol Sci 2008; 107: 285-94.
[68] Steri R, Achenbach J, Steinhilber D, Schubert-Zsilavecz M, Proschak E. Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol 2012; 83: 1674-81.
[69] Gao X, Fu T, Wang C, et al. Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury. Biochem Pharmacol 2017; 146: 127-38.
[70] El-hawary SS, Ali ZY, Younis IY. Hepatoprotective potential of standardized Ficus species in intrahepatic cholestasis rat model: involvement of nuclear factor-kappa B, and farnesoid X receptor signaling pathways. J Ethnopharmacol 2019; 231: 262-74.
[71] Gao X, Fu T, Wang C, et al. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro. Toxicol Appl Pharmacol 2018; 348: 105-16.
[72] Lin HR. Furocoumarins from Cnidium monnieri act as peroxisome proliferator-activated receptor gamma and farnesoid X receptor agonists. Mini Rev Org Chem 2016; 13: 88-96.
[73] Yang F, Tang X, Ding L, et al. Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation. Sci Rep 2016; 6: 33052.
[74] Raja Kumar S, Mohd Ramli ES, Abdul Nasir NA, Ismail NHM, Mohd Fahami NA. Preventive effect of naringin on metabolic syndrome and its mechanism of action: a systematic review. Evid Based Complement Alternat Med 2019; 2019: 9752826.
[75] Adil M, Kandhare AD, Ghosh P, Venkata S, Raygude KS, Bodhankar SL. Ameliorative effect of naringin in acetaminophen-induced hepatic and renal toxicity in laboratory rats: role of FXR and KIM-1. Ren Fail 2016; 38: 1007-20.
[76] Jung EH, Lee JH, Kim SC, Kim YW. AMPK activation by liquiritigenin inhibited oxidative hepatic injury and mitochondrial dysfunction induced by nutrition deprivation as mediated with induction of farnesoid X receptor. Eur J Nutr 2017; 56: 635-47.
[77] Zhang G, Liu S, Tan W, et al. Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid X receptor (FXR) antagonists. Eur J Med Chem 2017; 129: 303-9.
[78] Nozawa H. Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem Biophys Res Commun 2005; 336: 754-61.
[79] Chen X, Meng Q, Wang C, et al. Protective effects of calycosin against CCl4-induced liver injury with activation of FXR and STAT3 in mice. Pharm Res 2015; 32: 538-48.
[80] Lin HR, Chou TH, Huang DW, Chen IS. Cryptochinones from cryptocarya chinensis act as farnesoid X receptor agonists. Bioorg Med Chem Lett 2014; 24: 4181-6.
[81] Shanmugam S, Sivaraj D, Dos Santos Lima B, et al. Polyphenols rich passiflora leschenaultii leaves modulating farnesoid X receptor and pregnane X receptor against paracetamol-induced hepatotoxicity in rats. Biomed Pharmacother 2017; 88: 1114-21.
[82] Ma X, Zheng C, Hu C, Rahman K, Qin L. The genus Desmodium (Fabaceae)-traditional uses in chinese medicine, phytochemistry and pharmacology. J Ethnopharmacol 2011; 138: 314-32.
[83] Liu M, Zhang G, Wu S, et al. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor. J Ethnopharmacol 2020; 255: 112776.
[84] Zhao T, Tang H, Xie L, et al. Scutellaria baicalensis georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol 2019; 71: 1353-69.
[85] Yang J, Xiang D, Xiang D, et al. Baicalin protects against 17α-Ethinylestradiol-induced cholestasis via the Sirtuin 1/hepatic nuclear receptor-1α/farnesoid X receptor pathway. Front Pharmacol 2019; 10: 1685.
[86] Cermanova J, Kadova Z, Zagorova M, et al. Boldine enhances bile production in rats via osmotic and farnesoid X receptor dependent mechanisms. Toxicol Appl Pharmacol 2015; 285: 12-22.
[87] Sun R, Yang N, Kong B, et al. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway. Mol Pharmacol 2017; 91: 110-22.
[88] Ding L, Zhang B, Li J, Yang L, Wang Z. Beneficial effect of resveratrol on alphanaphthyl isothiocyanateinduced cholestasis via regulation of the FXR pathway. Mol Med Rep 2018; 17: 1863-72.
[89] Li G, Lin W, Araya JJ, Chen T, Timmermann BN, Guo GL. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol 2012; 258: 268-74.
[90] Liu B, Li Y, Ji H, Lu H, Li H, Shi Y. Glutamine attenuates obstructive cholestasis in rats via farnesoid X receptor-mediated regulation of Bsep and Mrp2. Can J Physiol Pharmacol 2017; 95: 215-23.
[91] Zheng Z, Zhao Z, Li S, et al. Altenusin, a nonsteroidal microbial metabolite, attenuates nonalcoholic fatty liver disease by activating the farnesoid X receptor. Mol Pharmacol 2017; 92: 425-36.
[92] Yang F, Wang Y, Li G, et al. Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo. Br J Pharmacol 2018; 175: 810-29.
[93] Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21: 159-65.
[94] Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015; 6: 10166.
[95] Sayin SI, Wahlstr?m A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17: 225-35.
[96] Prawitt J, Abdelkarim M, Stroeve JH, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861-71.
[97] Tu H, Okamoto AY, Shan B. FXR, a bile acid receptor and biological sensor. Trends Cardiovasc Med 2000; 10: 30-5.
[98] Beutler JA. Natural products as a foundation for drug discovery. Curr Protoc Pharmacol 2009; Chapter 9: Unit 9.11.
[99] Wang S, Du Q, Meng X, Zhang Y. Natural polyphenols: a potential prevention and treatment strategy for metabolic syndrome. Food Funct 2022; 13: 9734-53.
[100] Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nat Chem 2016; 8: 531-41.
[101] Zhang C, Liu Y, Wang Y, et al. Discovery of betulinic acid derivatives as potent intestinal farnesoid X receptor antagonists to ameliorate nonalcoholic steatohepatitis. J Med Chem 2022; 65: 13452-72.
[102] Fang Y, Hegazy L, Finck BN, Elgendy B. Recent advances in the medicinal chemistry of farnesoid X receptor. J Med Chem 2021; 64: 17545-71.
[103] Merk D, Sreeramulu S, Kudlinzki D, et al. Molecular tuning of farnesoid X receptor partial agonism. Nat Commun 2019; 10: 2915.
Options
Outlines

/

〈 〉